BioSpace News Archive

Eilean Therapeutics LLC announced the acquisition of Ness Therapeutics Inc in an all-equity transaction.

4M Therapeutics Inc., an early-stage biotechnology company developing treatments for neuropsychiatric and neurodegenerative conditions, announced the appointment of Kimberly Lee, D.O. as Chief Business Officer and member of the executive management team.

QurAlis Corporation today announced preclinical data that showed the company’s UNC13A splice-switching antisense oligonucleotides (ASOs) modulate UNC13A splicing and restore normal synaptic activities in ALS and FTD.

CytomX Therapeutics, Inc. today announced that it will report full year 2023 financial results on Monday, March 11, 2024, after the close of U.S. markets.

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced five presentations at the 2024 American Academy of Dermatology (AAD) annual meeting, which will take place in San Diego, CA from March 8 - 12, 2024.

BioCardia, Inc. (Nasdaq: BCDA), a biotechnology company focused on advancing late-stage cell therapy interventions for cardiovascular disorders, today announced positive interim results from the Phase III randomized controlled trial of its CardiAMP® autologous cell therapy in 110 randomized patients with advanced chronic heart failure at a mean 20-month follow-up, (CardiAMP HF).

Ventyx Biosciences, Inc. today announced that it will host a virtual investor event on Monday, March 11, 2024 from 11:00 a.m. to 12:30 p.m. ET.

CymaBay Therapeutics, Inc. announced that the Marketing Authorization Application for seladelpar, for the treatment of primary biliary cholangitis including pruritus in adults without cirrhosis or with compensated cirrhosis who are inadequate responders or intolerant to ursodeoxycholic acid), has been validated and will now be reviewed by the European Medicines Agency.

First Wave BioPharma, Inc., (NASDAQ: FWBI) announced today that it has entered into a definitive securities purchase agreement with a certain institutional investor for the purchase and sale of 525,625 shares of the Company’s common stock (or common stock equivalents) at a price of $7.61 per share in a registered direct offering.

vTv Therapeutics Inc. today announced the submission of the study protocol to the FDA for the Company’s first Phase 3 trial evaluating the safety and efficacy of its lead candidate, cadisegliatin , in adults diagnosed with T1D.